Drug · CHEMBL515
CHLORAMBUCIL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. CHLORAMBUCIL. Drugs and targets, record CHEMBL515. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL515
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Ambochlorin, CB-1348, Chlorambucilum, Clorambucilo, Ecloril, Lympholysin, NCI-3088, NSC-3088
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases18
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| B-cell chronic lymphocytic leukemia | Phase 3 | ClinicalTrials.gov | 27 | 27 | https://conductscience.org/library/drugs?q=MONDO_0004948 |
| Hodgkins lymphoma | Approval | DailyMed | 5 | 4 | https://conductscience.org/library/drugs?q=MONDO_0004952 |
| mantle cell lymphoma | Phase 2 | ClinicalTrials.gov | 4 | 4 | https://conductscience.org/library/drugs?q=MONDO_0018876 |
| non-Hodgkin lymphoma | Phase 3 | ClinicalTrials.gov | 3 | 3 | https://conductscience.org/library/drugs?q=MONDO_0018908 |
| MALT lymphoma | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0007650 |
| Waldenstrom macroglobulinemia | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0100280 |
| follicular lymphoma | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0018906 |
| lymphoplasmacytic lymphoma | Phase 3 | ClinicalTrials.gov | 2 | 2 | https://conductscience.org/library/drugs?q=MONDO_0000432 |
| focal segmental glomerulosclerosis | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0100313 |
| gastric lymphoma | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0001059 |
1 to 10 of 18Source Open Targets
See all 18 diseasesTrials47
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01905943 | A Safety and Efficacy Study of Obinutuzumab Alone or in Combination With Chemotherapy in Participants With Chronic Lymphocytic Leukemia | Phase 3 | 979 | 2018-10-29 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT01010061 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a) | Phase 3 | 787 | 2014-04-01 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | Phase 3 | 787 | 2014-01-28 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | Phase 3 | 787 | 2014-10-10 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT02475681 | Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL | Phase 3 | 535 | 2023-01-10 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT00210353 | Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma | Phase 3 | 454 | 2019-06-06 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT00910910 | Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial) | Phase 3 | 450 | 2016-12-21 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT00748189 | Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia | Phase 3 | 447 | 2014-03-26 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | Phase 3 | 445 | 2019-10-01 | chlorambucil | Its name | ClinicalTrials.gov |
| NCT01056510 | A Study of MabThera Added to Bendamustine or Chlorambucil in Patients With Chronic Lymphocytic Leukemia (MaBLe) | Phase 4 | 357 | 2015-06-25 | chlorambucil | Its name | ClinicalTrials.gov |
1 to 10 of 47
See all 47 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Rituximab + Chlorambucil (RClb) vs Obinutuzumab + Chlorambucil (GClb): serious adverse events | 124 of 321 | 150 of 336 | 657 | NCT02053610 | Trial comparisons |
| Lenalidomide vs Chlorambucil: Number of Participants Deaths During the Treatment and Survival Follow-Up Phase | 101 of 225 | 95 of 225 | 450 | NCT00910910 | Trial comparisons |
| Lenalidomide vs Chlorambucil: deaths from any cause | 100 of 224 | 93 of 223 | 447 | NCT00910910 | Trial comparisons |
| Lenalidomide vs Chlorambucil: serious adverse events | 148 of 224 | 90 of 223 | 447 | NCT00910910 | Trial comparisons |
| Chlorambucil vs Ofatumumab + Chlorambucil: Number of Participants With at Least One Grade 3/Grade 4 Myelosuppression (Anemia, Neutropenia, and Thrombocytopenia) | 92 of 227 | 83 of 217 | 444 | NCT00748189 | Trial comparisons |
| Chlorambucil vs Ofatumumab + Chlorambucil: Number of Participants With Autoimmune Hemolytic Anaemia (AIHA) Disease | 6 of 227 | 4 of 217 | 444 | NCT00748189 | Trial comparisons |
| Rituximab + Bendamustine vs Rituximab + Chlorambucil: serious adverse events | 73 of 177 | 56 of 178 | 355 | NCT01056510 | Trial comparisons |
| Rituximab + Chlorambucil (RClb) vs Chlorambucil (Clb): serious adverse events | 87 of 225 | 45 of 116 | 341 | NCT01998880 | Trial comparisons |
| PCI-32765 vs Chlorambucil: serious adverse events | 55 of 135 | 33 of 132 | 267 | NCT01722487 | Trial comparisons |
| Lenalidomide vs Investigator's Choice: deaths from any cause | 119 of 167 | 59 of 83 | 250 | NCT00875667 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials61
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL515
GET https://conductscience.org/api/drugs/v1/CHEMBL515/trials?page=2